Thomas Karn

Goethe University Frankfurt

Research Interests

Explore related searches

Contact this professor

Google Scholar

Articles (21)

Collaborators (6)

Lajos Pusztai

Yale University

UNITED STATES

Juliana Gonçalves

Technical University of Munich

Christine Solbach

Goethe University Frankfurt

Judith Lea Lindner

Kristina Schwamborn

Technical University of Munich

Paul Jank

Head of Translational Research Laboratory

Thomas Karn

Research Interests

Explore related searches

Contact this professor

Articles (21)

Collaborators (6)

Lajos Pusztai

Juliana Gonçalves

Christine Solbach

Judith Lea Lindner

Kristina Schwamborn

Paul Jank

How do I reach out?

Meet Kite AI

Thomas Karn

Research Interests

Explore related searches

Contact this professor

Articles (21)

Prognostic Impact of Estrogen and Progesterone Receptor Expression Across Histological Subtypes and Clinical Factors in Epithelial Ovarian Cancer

Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification

RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial

An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials

Prognostic impact of metabolic syndrome in patients with primary endometrial cancer: a retrospective bicentric study.

Baseline CD4<sup>+</sup> and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.

The clinical relevance of fractional curettage in the diagnostic management of primary endometrial cancer.

Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging

Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy

Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial.

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial.

The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patients.

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers

Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose dense doxorubicin/cyclophosphamide in basal-like triple negative breast cancer.

Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer

Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.

Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials.

Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer.

Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy.

Collaborators (6)

Lajos Pusztai

Juliana Gonçalves

Christine Solbach

Judith Lea Lindner

Kristina Schwamborn

Paul Jank

How do I reach out?

Meet Kite AI